NASDAQ:MEDP - Medpace Stock Price, Price Target & More

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace Holdings Inc (NASDAQ:MEDP) posted its quarterly earnings results on Monday, April, 30th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.43 by $0.17. The company had revenue of $108.40 million for the quarter, compared to analysts' expectations of $113.12 million. Medpace had a return on equity of 12.50% and a net margin of 10.37%. The firm's revenue was up 15.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.34 earnings per share. View Medpace's Earnings History.

Medpace is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Medpace.

Medpace issued an update on its FY18 earnings guidance on Monday, April, 30th. The company provided EPS guidance of $1.87-1.97 for the period, compared to the Thomson Reuters consensus estimate of $1.88. The company issued revenue guidance of $421-435 million, compared to the consensus revenue estimate of $463.04 million.

8 brokers have issued 1 year price targets for Medpace's shares. Their predictions range from $35.00 to $42.00. On average, they anticipate Medpace's stock price to reach $37.40 in the next twelve months. View Analyst Ratings for Medpace.

Medpace saw a decline in short interest in the month of May. As of May 15th, there was short interest totalling 267,456 shares, a decline of 47.9% from the April 30th total of 512,869 shares. Based on an average daily trading volume, of 536,998 shares, the days-to-cover ratio is presently 0.5 days. Currently, 2.3% of the company's shares are short sold.

Some companies that are related to Medpace include PRA Health Sciences (PRAH), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), Viralytics (VRACY), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI) and Luna Innovations (LUNA).

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Media headlines about MEDP stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Medpace earned a media sentiment score of 0.10 on Accern's scale. They also assigned headlines about the company an impact score of 46.61 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Medpace's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include CINVEN CAPITAL MANAGEMENT (V) GENERAL PARTNER LTD (37.70%), BlackRock Inc. (3.42%), Bernzott Capital Advisors (1.95%), UBS Group AG (0.91%), Granite Investment Partners LLC (0.73%) and Prudential Financial Inc. (0.50%). Company insiders that own Medpace stock include August J Troendle, Medpace Limited Partnership and Susan E Burwig. View Institutional Ownership Trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Alambic Investment Management L.P., Hsbc Holdings PLC, Federated Investors Inc. PA, Granite Investment Partners LLC, Thrivent Financial for Lutherans, Bernzott Capital Advisors and Wells Fargo & Company MN. View Insider Buying and Selling for Medpace.

MEDP stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, Dimensional Fund Advisors LP, American Century Companies Inc., Prudential Financial Inc., BlackRock Inc., Russell Investments Group Ltd., Allianz Asset Management GmbH and Allianz Asset Management GmbH. Company insiders that have bought Medpace stock in the last two years include August J Troendle and Susan E Burwig. View Insider Buying and Selling for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $45.24.

Medpace has a market capitalization of $1.61 billion and generates $436.15 million in revenue each year. The company earns $39.12 million in net income (profit) each year or $1.52 on an earnings per share basis. Medpace employs 2,500 workers across the globe.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]